ArticleVeterinary sciences2026
Comparative Phenotypic Characterization of Five CRISPR/Cas9-Generated Gene-Disrupted Mutants of Pseudorabies Virus JM Strain.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pseudorabies virus (PRV) is a neurotropic alphaherpesvirus that causes severe neurological and reproductive disease in swine and can infect a broad range of non-porcine mammals. To compare the phenotypic consequences associated with disruption of different PRV genes within a uniform genetic background, UL21, UL24, UL50, UL56, and gG (US4) were individually disrupted in the PRV JM strain using CRISPR/Cas9. The resulting gene-disrupted viruses were characterized by multi-step growth analysis, plaque formation, and experimental infection in mice. The five viruses displayed distinct and non-parallel phenotypic profiles. PRV JM-ΔUL24, PRV JM-ΔUL50, PRV JM-ΔUL56, and PRV JM-ΔgG showed reduced peak extracellular viral titers, whereas PRV JM-ΔUL21 exhibited only a limited change in viral growth. In contrast, markedly smaller plaques were observed for PRV JM-ΔUL21 and PRV JM-ΔUL56, indicating that extracellular viral yield and plaque phenotype were not necessarily concordant. In mice, PRV JM-ΔUL21 and PRV JM-ΔUL24 showed delayed mortality and 40% survival, whereas PRV JM-ΔUL50 caused delayed but complete mortality and PRV JM-ΔUL56 and PRV JM-ΔgG retained survival patterns similar to parental PRV JM. Thus, attenuation in vivo was not directly predicted by impaired replication or plaque formation in vitro. Among the five gene-disrupted viruses examined, PRV JM-ΔUL21 and PRV JM-ΔUL24 showed the most pronounced attenuation-associated phenotypes in the mouse model, although substantial residual virulence remained. These comparative findings identify UL21 and UL24 as priority loci for further mechanistic evaluation and for assessment in future multi-gene attenuation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.